Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Apr 2026 According to a Pharvaris media release, company anticipates announcing topline data from the trial in third quarter of 2026.
02 Apr 2026 Status changed from recruiting to active, no longer recruiting.
10 Feb 2026 According to a Pharvaris media release, data from this trial will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, to be held from February 27-March 2, 2026, in Philadelphia, PA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com